According to the First Pharmaceutical announcement, on August 7, August 10, and August 11, 2026, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for three consecutive trading days, which was an abnormal fluctuation. After self-inspection, the company's business activities are normal, the business has not changed, and there have been no major adjustments to industry policies. The company and controlling shareholders have no material information that should have been disclosed but not disclosed, and no cases of trading in the company's shares have been discovered by directors, supervisors, controlling shareholders, and their co-actors. Remind investors to be aware of risks and invest rationally.

According to the First Pharmaceutical announcement, on August 7, August 10, and August 11, 2026, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for three consecutive trading days, which was an abnormal fluctuation. After self-inspection, the company's business activities are normal, the business has not changed, and there have been no major adjustments to industry policies. The company and controlling shareholders have no material information that should have been disclosed but not disclosed, and no cases of trading in the company's shares have been discovered by directors, supervisors, controlling shareholders, and their co-actors. Remind investors to be aware of risks and invest rationally.